WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Moderator

Armin Wolf, MD

Professor of Ophthalmology
Director
Department of Ophthalmology
University of Ulm
Ulm, Germany

Disclosures

Armin Wolf, MD, has the following relevant financial relationships:
Consultant or advisor for: Apellis Pharmaceuticals; Bayer; Novartis; Roche
Speaker or member of speakers bureau for: Bayer; Novartis; Roche
Contracted researcher for: Boehringer Ingelheim Pharmaceuticals, Inc.; Zeiss Meditec

Faculty

Carl D. Regillo, MD

Director
Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Philadelphia, Pennsylvania, United States

Disclosures

Carl D. Regillo, MD, has the following relevant financial relationships:
Consultant or advisor for: 4DMT; Adverum Biotechnologies; Allergan; Annexon; Apellis Pharmaceuticals; Aviceda Therapeutics; Bausch & Lomb, Inc.; Clearside Biomedical; EyePoint Pharmaceuticals, Inc.; Genentech; IVERIC bio, Inc.; Janssen Biotech, Inc.; Kodiak Sciences; Lineage Cell Therapeutics, Inc.; Merck; NGM Biopharmaceuticals; Novartis; Ocugen, Inc.; Ocular Therapeutics; Opthea; Ray Pharma; Regenxbio Inc; Stealth BioTherapeutics Inc.; Thea Pharma, Inc.; Zeiss
Research funding from: Adverum Biotechnologies; Allergan; Annexon; Apellis Pharmaceuticals; Astellas Pharma, Inc.; Eyepoint Pharmaceuticals, Inc; Genentech; Gyroscope; IVERIC bio, Inc.; Kodiak Sciences; Lineage Cell Therapeutics, Inc; NGM Biopharmaceuticals; Notal Vision, Inc.; Novartis; Ocugen, Inc.; Opthea; Regeneron Pharmaceuticals, Inc.; Regenxbio, Inc.
Contracted researcher for: Adverum Biotechnologies; Annexon; Apellis; Astellas Pharma, Inc.; Eyepoint Pharmaceuticals, Inc.; Genentech; Gyroscope; IVERIC bio, Inc.; Kodiak Sciences; Lineage Cell Therapeutics, Inc.; NGM Biopharmaceuticals; Notal Vision, Inc.; Novartis; Ocugen, Inc.; Opthea; Regeneron Pharmaceuticals, Inc.; Regenxbio, Inc.
Stock options from: Aviceda Therapeutics; Ocugen, Inc.

Carl Awh, MD, FASRS

President
Tennessee Retina
Nashville, Tennessee, United States

Disclosures

Carl Awh, MD, FASRS, has the following relevant financial relationships:
Consultant or advisor for: Bausch & Lomb Inc.; Genentech; Katalyst Surgical (former)
Research funding from: Adverum Biotechnologies; Apellis Pharmaceuticals; Astellas Pharma, Inc.; Genentech; Kodiak Sciences; Mylan Laboratories Inc.; Oxurion; Regeneron Pharmaceuticals, Inc.; Regenxbio, Inc.
Royalties from: Bausch & Lomb Inc.
Stock options from: ArcticDX

Margaret A. Chang, MD, MS

Senior Partner
Retinal Consultants
Sacramento, California, United States

Disclosures

Margaret A. Chang, MD, MS, has the following relevant financial relationships:
Consultant or advisor for: IVERIC bio, Inc.; Genentech; Regenxbio, Inc.
Research funding from: Allergan, Inc.; EyeBio; Meylan; NGM Biopharmaceuticals; Novartis; OcuTerra Therapeutics; Opthea; Regeneron Pharmaceuticals, Inc.

Jordan M. Graff, MD, FACS

Clinical Assistant Professor of Ophthalmology
University of Arizona Phoenix
Clinical Assistant Professor
Creighton University
Surgeon and Partner
Barnet Dulaney Perkins Eye Center
Phoenix, Arizona, United States

Disclosures

Jordan M. Graff, MD, FACS, has the following relevant financial relationships:
Consultant or advisor for: HiHealth; Regenxbio; Roche/Genentech
Speaker or member of speakers bureau for: Roche/Genentech
Research funding from: Allergan; Regeneron Pharmaceuticals, Inc.; Regenxbio, Inc.; Roche/Genentech

Editor

Katherine Carpenter, PhD

Medical Education Director, WebMD Global, LLC

Disclosures

Katherine Carpenter, PhD, has the following relevant financial relationships:
Consultant or advisor for: Eisai, Inc. (former)

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

CPD

Retinal Disease: An Update on Emerging Technologies

Authors: Armin Wolf, MD; Carl D. Regillo, MD; Carl Awh, MD, FASRS; Margaret A. Chang, MD, MS; Jordan M. Graff, MD, FACS
CPD Released: 8/30/2023
Valid for credit through: 8/30/2024, 11:59 PM EST

Start Activity

Credits Available

Non-US Physicians - maximum of 0.75 CPD

You Are Eligible For
- Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US retina specialists, ophthalmologists, optometrists, diabetologists, and all physicians who care for patients with retinal diseases.

The goal of this activity is for learners to be better able to identify patients with retinal diseases who might benefit from new and emerging technology.

Upon completion of this activity, participants will:

Have increased knowledge regarding the

Anti-vascular epithelial growth factor (VEGF) implants and other emerging technologies
Rationale for new technologies in managing retinal disease
Latest data on emerging technologies in neovascular age-related macular degeneration (nAMD)
Latest data with emerging technologies in diabetic eye disease

Disclosures

Moderator

Armin Wolf, MD

Professor of Ophthalmology
Director
Department of Ophthalmology
University of Ulm
Ulm, Germany

Disclosures

Armin Wolf, MD, has the following relevant financial relationships:
Consultant or advisor for: Apellis Pharmaceuticals; Bayer; Novartis; Roche
Speaker or member of speakers bureau for: Bayer; Novartis; Roche
Contracted researcher for: Boehringer Ingelheim Pharmaceuticals, Inc.; Zeiss Meditec

Faculty

Carl D. Regillo, MD

Director
Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Philadelphia, Pennsylvania, United States

Disclosures

Carl D. Regillo, MD, has the following relevant financial relationships:
Consultant or advisor for: 4DMT; Adverum Biotechnologies; Allergan; Annexon; Apellis Pharmaceuticals; Aviceda Therapeutics; Bausch & Lomb, Inc.; Clearside Biomedical; EyePoint Pharmaceuticals, Inc.; Genentech; IVERIC bio, Inc.; Janssen Biotech, Inc.; Kodiak Sciences; Lineage Cell Therapeutics, Inc.; Merck; NGM Biopharmaceuticals; Novartis; Ocugen, Inc.; Ocular Therapeutics; Opthea; Ray Pharma; Regenxbio Inc; Stealth BioTherapeutics Inc.; Thea Pharma, Inc.; Zeiss
Research funding from: Adverum Biotechnologies; Allergan; Annexon; Apellis Pharmaceuticals; Astellas Pharma, Inc.; Eyepoint Pharmaceuticals, Inc; Genentech; Gyroscope; IVERIC bio, Inc.; Kodiak Sciences; Lineage Cell Therapeutics, Inc; NGM Biopharmaceuticals; Notal Vision, Inc.; Novartis; Ocugen, Inc.; Opthea; Regeneron Pharmaceuticals, Inc.; Regenxbio, Inc.
Contracted researcher for: Adverum Biotechnologies; Annexon; Apellis; Astellas Pharma, Inc.; Eyepoint Pharmaceuticals, Inc.; Genentech; Gyroscope; IVERIC bio, Inc.; Kodiak Sciences; Lineage Cell Therapeutics, Inc.; NGM Biopharmaceuticals; Notal Vision, Inc.; Novartis; Ocugen, Inc.; Opthea; Regeneron Pharmaceuticals, Inc.; Regenxbio, Inc.
Stock options from: Aviceda Therapeutics; Ocugen, Inc.

Carl Awh, MD, FASRS

President
Tennessee Retina
Nashville, Tennessee, United States

Disclosures

Carl Awh, MD, FASRS, has the following relevant financial relationships:
Consultant or advisor for: Bausch & Lomb Inc.; Genentech; Katalyst Surgical (former)
Research funding from: Adverum Biotechnologies; Apellis Pharmaceuticals; Astellas Pharma, Inc.; Genentech; Kodiak Sciences; Mylan Laboratories Inc.; Oxurion; Regeneron Pharmaceuticals, Inc.; Regenxbio, Inc.
Royalties from: Bausch & Lomb Inc.
Stock options from: ArcticDX

Margaret A. Chang, MD, MS

Senior Partner
Retinal Consultants
Sacramento, California, United States

Disclosures

Margaret A. Chang, MD, MS, has the following relevant financial relationships:
Consultant or advisor for: IVERIC bio, Inc.; Genentech; Regenxbio, Inc.
Research funding from: Allergan, Inc.; EyeBio; Meylan; NGM Biopharmaceuticals; Novartis; OcuTerra Therapeutics; Opthea; Regeneron Pharmaceuticals, Inc.

Jordan M. Graff, MD, FACS

Clinical Assistant Professor of Ophthalmology
University of Arizona Phoenix
Clinical Assistant Professor
Creighton University
Surgeon and Partner
Barnet Dulaney Perkins Eye Center
Phoenix, Arizona, United States

Disclosures

Jordan M. Graff, MD, FACS, has the following relevant financial relationships:
Consultant or advisor for: HiHealth; Regenxbio; Roche/Genentech
Speaker or member of speakers bureau for: Roche/Genentech
Research funding from: Allergan; Regeneron Pharmaceuticals, Inc.; Regenxbio, Inc.; Roche/Genentech

Editor

Katherine Carpenter, PhD

Medical Education Director, WebMD Global, LLC

Disclosures

Katherine Carpenter, PhD, has the following relevant financial relationships:
Consultant or advisor for: Eisai, Inc. (former)

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.75 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

Retinal Disease: An Update on Emerging Technologies

Authors: Armin Wolf, MD; Carl D. Regillo, MD; Carl Awh, MD, FASRS; Margaret A. Chang, MD, MS; Jordan M. Graff, MD, FACSFaculty and Disclosures

CPD Released: 8/30/2023

Valid for credit through: 8/30/2024, 11:59 PM EST

processing....

Contents of this Activity

To start this activity, please assess your clinical knowledge by completing the brief survey at the bottom. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Overview of Program

Dr Wolf introduces the program.
Armin Wolf, MD

Beyond Intravitreal Injections in Retinal Disease: Injections vs Emerging Technologies

How can we ease the burden of repeated injections on our clinics and our patients? Dr Regillo explains the approaches to extending treatment intervals and the intervals they might achieve.
Carl D. Regillo, MD

Latest Clinical Data for Emerging Technologies: Neovascular Age-Related Macular Degeneration

How do these approaches perform in controlling age-related macular degeneration (AMD)?
Carl Awh, MD, FASRS

Latest Clinical Data for Emerging Technologies: Diabetic Eye Disease

How do these approaches perform in controlling diabetic retinopathy and macular edema, and how do you select suitable patients?
Margaret A. Chang, MD, MS; Jordan M. Graff, MD, FACS

Safety Considerations With Emerging Technologies

What are the risks with these approaches, and how can we mitigate those risks?
Jordan M. Graff, MD, FACS

Patient Perspectives: Treatment of Retinal Diseases

What factors drive patients' acceptance of treatment, and what do they prefer?
Margaret A. Chang, MD

Conclusions

Dr Wolf summarizes the program.
Armin Wolf, MD

Educational Impact Challenge

Please answer the questions below to self-assess your knowledge. Answering these questions again after the activity will allow you to see what you learned.

Page 1 of 10

CPD Information Download Slides

Activity Transcript

Print
Like Tweet

Activity Transcript

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.

The material presented here does not necessarily reflect the views of WebMD, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been authorized by the European Medicines Agency for use in Europe, off-label uses of authorized products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Moderator

Armin Wolf, MD

Faculty

Carl D. Regillo, MD

Carl Awh, MD, FASRS

Margaret A. Chang, MD, MS

Jordan M. Graff, MD, FACS

Editor

Katherine Carpenter, PhD

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Peer Reviewer

CPD

Retinal Disease: An Update on Emerging Technologies

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Moderator

Armin Wolf, MD

Faculty

Carl D. Regillo, MD

Carl Awh, MD, FASRS

Margaret A. Chang, MD, MS

Jordan M. Graff, MD, FACS

Editor

Katherine Carpenter, PhD

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Retinal Disease: An Update on Emerging Technologies

Contents of this Activity

Overview of Program

Beyond Intravitreal Injections in Retinal Disease: Injections vs Emerging Technologies

Latest Clinical Data for Emerging Technologies: Neovascular Age-Related Macular Degeneration

Latest Clinical Data for Emerging Technologies: Diabetic Eye Disease

Safety Considerations With Emerging Technologies​

Patient Perspectives: Treatment of Retinal Diseases

Conclusions

Educational Impact Challenge

Safety Considerations With Emerging Technologies